HR Execs on the Move

ImmunoGen

www.immunogen.com

 
Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Isabel Kalofonos
 Senior Vice President and Chief Commercial Officer Profile
Susan Altschuller
 CFO Profile
Renee Lentini
 Interim CFO Profile
Brenda Som
 Associate Director of Total Rewards Profile
Maurisa Croce
 VP, Product Team Leader Profile

Similar Companies

ConceptionNurs

Hookipa Pharma

Hookipa Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body`s immune system. HOOKIPA`s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA`s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system. HOOKIPA`s VaxWave®-based prophylactic cytomegalovirus vaccine candidate is currently in a Phase 2 clinical trial in patients awaiting kidney transplantation from living cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.

William Gallagher Associates

William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

HiberCell

Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.

GenSpera

GenSpera, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.